Rockwell Medical(RMTI)

WIXOM, MIBiotechnology3 H-1B visas (FY2023)

Focus: Rockwell Medical is a public biotechnology company specializing in dialysis products and nephrology therapeutics, with a focused portfolio centered on iron supplementation for renal patients. The company generated $101M in FY 2025 revenue with a market cap implied by ticker RMTI.

Nephrology

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Rockwell Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Rockwell Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

3 in 5yr

TRIFERIC

Hiring

Stable

Revenue

$101M

Key Products

TRIFERIC AVNU

Iron supplementation in end-stage renal disease

Peak3.0yr

Lead franchise with 4+ years of patent protection; primary commercial driver for the company.

Help build intelligence for Rockwell Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Peak-stage commercial product (TRIFERIC AVNU with ferric pyrophosphate citrate) protected until 2029, providing 5+ years of market exclusivity
Niche market focus in nephrology offers deep domain expertise and focused career trajectory in a specialized therapeutic area with stable patient populations
Public company status with growing revenue ($101M FY2025 vs $84M FY2024, +20% YoY) suggests reinvestment and potential for advancement

Watch Out For

Razor-thin R&D spend ($19K FY2025) indicates minimal internal pipeline development and limited R&D career opportunities or innovation-driven culture
Negative net income in both reported periods ($-480K FY2025, $-8.4M FY2024) despite revenue growth raises profitability and long-term stability concerns
Zero active job openings reported and likely lean headcount suggest limited hiring and career mobility within the organization
Highly concentrated portfolio with only two marketed products (TRIFERIC variants and CALCITRIOL generic) creates vulnerability to market shifts or competitive pressure

Pipeline & Clinical Trials

soluble ferric pyrophosphate

End Stage Renal Disease (ESRD)

N/A

Clinical Trials (1)

NCT00604565Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients

N/A

soluble ferric pyrophosphate

Kidney Failure, Chronic Therapy; Hemodialysis

PHASE_1

Clinical Trials (1)

NCT01920854A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.

Phase 1

Triferic

Peritoneal Dialysis (PD)

PHASE_1

Clinical Trials (1)

NCT02909153Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis

Phase 1

Triferic

End Stage Renal Disease

PHASE_1

Clinical Trials (1)

NCT02636049Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

Phase 1

Triferic

End Stage Renal Disease

PHASE_1

Clinical Trials (1)

NCT02739100Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Phase 1

Triferic

Iron-refractory, Iron-deficiency Anemia (IRIDA)

PHASE_1

Clinical Trials (1)

NCT02767128Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

Phase 1

Triferic

End Stage Renal Disease

PHASE_1_2

Clinical Trials (1)

NCT04042324A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

Phase 1/2

Triferic

End Stage Renal Disease

PHASE_1_2

Clinical Trials (1)

NCT02595437Triferic Pediatric Pharmacokinetic Protocol

Phase 1/2

Triferic

End Stage Renal Disease

PHASE_1_2

Clinical Trials (1)

NCT03303144Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Phase 1/2

Triferic

End Stage Renal Disease

PHASE_1_2

Clinical Trials (1)

NCT04409132Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

Phase 1/2

Soluble Ferric Pyrophosphate

Kidney Failure

PHASE_1_2

Clinical Trials (1)

NCT01894906Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

Phase 1/2

Soluble Ferric Pyrophosphate in liquid bicarbonate

End Stage Renal Disease

PHASE_2

Clinical Trials (1)

NCT01286012Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Phase 2

Fer-In-Sol

Iron-Refractory Iron-Deficiency Anemia

PHASE_2

Clinical Trials (1)

NCT02905981Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol

Phase 2

Triferic AVNU

Iron Deficiency Anemia

PHASE_2

Clinical Trials (1)

NCT05110768Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy

Phase 2

Standard Bicarbonate Solution

End-Stage Renal Disease (ESRD)

PHASE_2

Clinical Trials (1)

NCT00548249Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis

Phase 2

SFP

End Stage Renal Disease

PHASE_3

Clinical Trials (1)

NCT01503021Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

Phase 3

Triferic

End Stage Renal Disease

PHASE_3

Clinical Trials (1)

NCT04239391Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

Phase 3

Soluble Ferric Pyrophosphate

Renal Failure Chronic Requiring Hemodialysis

PHASE_3

Clinical Trials (1)

NCT01322347Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

Phase 3

Soluble Ferric Pyrophosphate

Renal Failure Chronic Requiring Hemodialysis

PHASE_3

Clinical Trials (1)

NCT01320202Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Phase 3

Triferic AVNU

End Stage Renal Disease

PHASE_4

Clinical Trials (1)

NCT04689932Triferic AVNU Infusion Via Freedom Pump During Hemodialysis

Phase 4

Interview Prep Quick Facts

Portfolio: 4 approved products, 20 clinical trials

Top TAs: Nephrology, Hematology, Endocrinology

H-1B (2023): 3 approvals

SEC Filings: 2 available

Portfolio Health

Peak3 (75%)

Post-LOE1 (25%)

4 total products

Therapeutic Area Focus

Nephrology

1 marketed17 pipeline

Hematology

4 pipeline

Endocrinology

1 marketed

Marketed

Pipeline

Financials (FY2025)

Revenue

$101M21%

R&D Spend

$19K(0%)98%

Net Income

-$480K

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Rockwell Medical(RMTI)

About Rockwell Medical

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Pipeline & Clinical Trials

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship